ライフサイエンスコーパス: Kaplan

1 Kaplan Meier survival analysis showed significantly shor

2 Kaplan-Meier 20-year survival was 31%.

3 Kaplan-Meier 5 year estimates of MACCE were 29% for PCI

4 Kaplan-Meier analyses revealed a flat PTC-specific patie

5 Kaplan-Meier analysis demonstrated a 5-year OS of 81% in

6 Kaplan-Meier analysis demonstrated a lower risk for graf

7 Kaplan-Meier analysis demonstrated an increased risk of

8 Kaplan-Meier analysis demonstrated complete success rate

9 Kaplan-Meier analysis demonstrated that ADT users 70 yea

10 Kaplan-Meier analysis indicated a shorter survival time

11 Kaplan-Meier analysis of disease-free survival and overa

12 Kaplan-Meier analysis of graft and patient survival foun

13 Kaplan-Meier analysis of overall survival (OS), progress

14 Kaplan-Meier analysis revealed a stepwise increase in mo

15 Kaplan-Meier analysis revealed that patients on hemodial

16 Kaplan-Meier analysis showed a mean time of recurrence o

17 Kaplan-Meier analysis showed no differences in the incid

18 Kaplan-Meier analysis showed statistically significant d

19 Kaplan-Meier analysis showed that the 1-, 5-, and 10-yea

20 Kaplan-Meier analysis showed that the complete success r

21 Kaplan-Meier analysis showed worse survival for patients

22 Kaplan-Meier analysis was performed for PTLD-free surviv

23 Kaplan-Meier analysis was used to estimate freedom from

24 Kaplan-Meier analysis, log-rank tests, Fine and Gray com

25 Kaplan-Meier and Cox proportional hazards analyses were

26 Kaplan-Meier and Cox proportional hazards models were us

27 Kaplan-Meier and Cox regression analyses were performed.

28 Kaplan-Meier and Cox regression models were used to test

29 Kaplan-Meier curve analysis indicated that the AS group

30 Kaplan-Meier curve reconstruction did not show significa

31 Kaplan-Meier curve was significantly different between g

32 Kaplan-Meier curves and adjusted Cox models were used to

33 Kaplan-Meier curves and univariable and multivariable Co

34 Kaplan-Meier curves showed 1-year survival after first s

35 Kaplan-Meier curves showed that reduced Ks and prolonged

36 Kaplan-Meier curves were compared by using log-rank test

37 Kaplan-Meier curves were used to explore the association

38 Kaplan-Meier estimate for absence of metastatic disease

39 Kaplan-Meier estimate for local control at 5 years was 7

40 Kaplan-Meier estimate for melanoma-related metastasis in

41 Kaplan-Meier estimate of relapse revealed patients with

42 Kaplan-Meier estimate of the incidence of TIA /stroke wi

43 Kaplan-Meier estimates and Cox proportional hazard regre

44 Kaplan-Meier estimates and Cox proportional hazards regr

45 Kaplan-Meier estimates for the PFS at 1, 5, and 10 years

46 Kaplan-Meier estimates of the cumulative incidence were

47 Kaplan-Meier estimates of the primary endpoint across gr

48 Kaplan-Meier estimates of the stroke rate at days 2, 7,

49 Kaplan-Meier estimates results were similar in the per-p

50 Kaplan-Meier estimates showed a reduction in the seconda

51 Kaplan-Meier estimates were used for OS analyses.

52 Kaplan-Meier estimates were used to investigate time to

53 Kaplan-Meier estimation and Cox proportional hazards mod

54 Kaplan-Meier estimation was performed, and 95% confidenc

55 Kaplan-Meier estimation was used for survival analysis w

56 Kaplan-Meier incidence over 4 years was 0.042 (95% CI, 0

57 Kaplan-Meier method and Cox regression were used to eval

58 Kaplan-Meier method and Cox regression were used to eval

59 Kaplan-Meier method estimated the probability of glaucom

60 Kaplan-Meier methods were used to determine treatment fa

61 Kaplan-Meier survival analysis did not demonstrate a dif

62 Kaplan-Meier survival analysis showed increased risk of

63 Kaplan-Meier survival curves and log-rank tests revealed

64 Kaplan-Meier survival curves assessed the timing of init

65 Kaplan-Meier survival curves estimated the time from ini

66 Kaplan-Meier survival curves rapidly declined with incre

67 d 21.3% after 5 years, P = .001 and P = .01 [Kaplan-Meier], respectively) compared with the comparato

68 37.4% after 5 years, P = .001 and P = .048 [Kaplan-Meier], respectively) and less neovascular glauco

69 Week 24 Kaplan-Meier estimates of PTDM were similar for arm 1 ve

70 A Kaplan-Meier analysis was performed to estimate time to

71 A Kaplan-Meier curve analysis revealed that the cumulative

72 A Kaplan-Meier estimate of the median time to melanoma amo

73 A Kaplan-Meier survival analysis evaluated survival experi

74 learance kinetics, measured every 6 h, and a Kaplan-Meier analysis to compare parasite clearance kine

75 Visual acuity, Kaplan-Meier estimates of survival, local control, metas

76 lity of treatment weighting (IPTW) -adjusted Kaplan-Meier curves and Cox proportional hazards regress

77 IPTW-adjusted Kaplan-Meier curves showed that median OS was significan

78 IPTW-adjusted Kaplan-Meier curves showed that median OS was significan

79 The adjusted Kaplan-Meier curves showed significantly lower survival

80 The aggregated Kaplan-Meier analysis of immunotherapy trials vs chemoth

81 10 years using the Greenwood-Nam-D'Agostino Kaplan-Meier approach to account for dropout and loss to

82 ting-characteristic (ROC) curve analysis and Kaplan-Meier survival curves.

83 nd overall survival were compared by chi and Kaplan-Meier method, respectively.

84 t, Kruskal-Wallis, Spearman correlation, and Kaplan-Meier estimates; Cox regression models were perfo

85 ed on tumor size and necrosis criteria), and Kaplan-Meier survival time.

86 (OS); described using cumulative-hazard and Kaplan-Meier plots and multivariable analyses by Flexibl

87 Cox proportional-hazard modeling and Kaplan-Meier analyses were used to estimate long-term OS

88 Using unadjusted and adjusted Cox models and Kaplan-Meier analysis, there was no significant differen

89 mined by Cox proportional hazards models and Kaplan-Meier method.

90 x proportional hazards regression models and Kaplan-Meier survival analysis.

91 absolute risks by calculating prevalence and Kaplan-Meier estimates.

92 Sharing, competing risk, Cox regression and Kaplan-Meier analyses were performed on first-time liver

93 hted Cox proportional hazards regression and Kaplan-Meier curves.

94 stics, multivariate logistic regression, and Kaplan-Meier survival analyses.

95 nd morbidity attributable to resistance, and Kaplan-Meier plots to analyze survival differences.

96 which was significant in both chi-square and Kaplan-Meier analysis.

97 n rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis.

98 We applied Kaplan-Meier analysis for survival curves and mortality

99 By Kaplan-Meier analysis, 5-year survival was 35.7% (95% co

100 By Kaplan-Meier analysis, event-free survival was significa

101 By Kaplan-Meier analysis, VA less than 20/200 at 3 years wa

102 ied end point and 21% (95% CI, 7% to 26%) by Kaplan-Meier estimate in a post hoc analysis using metho

103 ative risk of treatment failure by day 28 by Kaplan-Meier analysis.

104 < 3 years), and 20% (95% CI, 10% to 37%) by Kaplan-Meier estimate in post hoc analysis using definit

105 lly meaningful deterioration was analysed by Kaplan-Meier methods.

106 Data were analyzed by Kaplan-Meier log-rank test and Cox regression analysis (

107 Breast cancer-specific survival assessed by Kaplan-Meier analyses and multivariate Cox proportional

108 associated genetic variants were assessed by Kaplan-Meier analysis.

109 (PFS) and overall survival (OS) assessed by Kaplan-Meier estimates.

110 ngitudinal shedding rates were determined by Kaplan-Meier survival analysis.

111 ncoded nucleosome organization discovered by Kaplan et al Our results establish an important connecti

112 Survival was estimated by Kaplan-Meier method and log-rank test.

113 se Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covar

114 ospital all-cause mortality was evaluated by Kaplan-Meier curves and Cox proportional hazard modeling

115 Three-year rates by Kaplan-Meier estimate were 72% (95% CI, 56% to 84%) for

116 ormed by descriptive methods and survival by Kaplan-Meier curves.

117 We calculated Kaplan-Meier probability estimates and Cox proportional

118 apy, and other trials were pooled to compare Kaplan-Meier survival estimates in the 3 therapeutic cla

119 We constructed Kaplan-Meier estimates and applied parametric survival a

120 We created Kaplan-Meier curves and constructed multivariable Cox pr

121 Receiver operating characteristic curve, Kaplan-Meier method, Cox regression, and classification

122 mated "freedom of incisional hernia" curves (Kaplan-Meier estimate) were significantly different acro

123 EF was measured with the Delis-Kaplan Executive Function System (DKEFS: performance bas

124 Survival analysis employed Kaplan-Meier curves and adjusted Cox proportional hazard

125 mes were assessed using frequency of events, Kaplan-Meier curves, and Cox proportional hazards regres

126 Five- and 10-year metastasis-free Kaplan-Meier estimates for the recurrence-free group wer

127 ues of 34 mL/m(2) for LAVI and -15% for GLS, Kaplan-Meier survival curves showed significant better s

128 Importantly, Kaplan-Meier survival analysis indicated that elevated K

129 In Kaplan-Meier analyses, low iron levels (cutoff 10.5 mumo

130 In Kaplan-Meier analysis over a 5-year follow-up period, su

131 as more likely in group 1 than in group 2 in Kaplan-Meier analysis (Log Rank P=0.04).

132 ables, and other biomarkers were analyzed in Kaplan-Meier log-rank survival analysis and then multiva

133 roups (P > 0.05 for all but 1 comparison) in Kaplan-Meier survival analyses.

134 d placebo groups, respectively, resulting in Kaplan-Meier estimates of 77.2% (95% CI 71.87-82.51) of

135 Survival analysis included Kaplan-Meier curves and Cox regressions.

136 t had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95).

137 The 18-month Kaplan-Meier estimates of disease-free survival were sig

138 The 36-month Kaplan-Meier estimates of ocular survival were 83.3% (95

139 routine PPI co-prescription on the basis of Kaplan-Meier risk estimates and relative risk reduction

140 nd GEP class) was performed by comparison of Kaplan-Meier event rate curves and univariate Cox propor

141 to 1.48; P=0.43); event rates were based on Kaplan-Meier estimates in time-to-event analyses.

142 Event rates were based on Kaplan-Meier estimates in time-to-first-event analyses.

143 significant differences in mortality risk on Kaplan-Meier analyses (P </= 0.002 for all PET/CT-based

144 Five-year disease-free survival on Kaplan-Meier analysis was 82%, and 5-year overall surviv

145 median follow-up of 5.2 (3.6, 6.9) years on Kaplan-Meier analysis, a significant nonlinear associati

146 Endpoints included overall Kaplan-Meier estimates for hernia recurrence and postope

147 The overall Kaplan-Meier survival probability was 80% (95% confidenc

148 s there were 343 VTE events in 301 patients (Kaplan-Meier rate at 3 years, 0.9% for placebo).

149 Among the 973 CABG and 2255 PCI patients, Kaplan-Meier major adverse cardiac event-free survival c

150 Primary patency per Kaplan-Meier estimates at day 365 was 82.3% for DCB vers

151 observed in progression-free survival (PFS) (Kaplan-Meier P value = 0.0166) between patients designat

152 s to develop a mathematical model to predict Kaplan-Meier survival curves for chemotherapy combined w

153 basis of personalized cytogenetic profiles, Kaplan-Meier estimates (1, 3, and 5 years) for melanoma-

154 lated with the 21-gene RS by using log-rank, Kaplan-Meier, and Cox regression.

155 Descriptive statistics, incidence rates, Kaplan-Meier survival curves, and the RR of NLP outcomes

156 ialysis and Transplant Association Registry, Kaplan-Meier, competing risk, and Cox regression analyse

157 Bi- and multivariable logistic regression, Kaplan-Meier analysis, and Cox proportional hazards mode

158 tory abilities of inflammation-based scores; Kaplan-Meier analysis was performed to plot the survival

159 Long-term Kaplan-Meier (K-M) survival rates for those with and wit

160 sing a Cox hazards model, the log-rank test, Kaplan-Meier curves, competing-risks regression, and con

161 tistical analysis included chi-square tests, Kaplan-Meier survival curves, and Cox proportional-hazar

162 The Kaplan-Meier curves did not differ both for complete and

163 The Kaplan-Meier curves showed significant differences in fa

164 The Kaplan-Meier estimate of the 1-year event rate of the co

165 The Kaplan-Meier estimate of the rate of the primary safety

166 The Kaplan-Meier estimated medians for duration of response,

167 The Kaplan-Meier estimates of mortality at day 60 did not di

168 The Kaplan-Meier event rate of spontaneous MI through 30 mon

169 The Kaplan-Meier method and Cox regression analyses were use

170 The Kaplan-Meier method and Cox regression analysis were per

171 The Kaplan-Meier method and Cox regression were used for the

172 The Kaplan-Meier method was used for survival analyses.

173 The Kaplan-Meier method was used to calculate 5-year overall

174 The Kaplan-Meier method was used to calculate the cumulative

175 The Kaplan-Meier method was used to estimate DSS, and Cox pr

176 The Kaplan-Meier method was used to obtain cumulative probab

177 The Kaplan-Meier method with the log-rank test was performed

178 The Kaplan-Meier survival probability at 1 year was similar

179 The Kaplan-Meier time-to-event analyses showed that OCT dete

180 The Kaplan-Meier-estimated 6-month transition rates were 5.1

181 We used stepwise Cox regression and the Kaplan-Meier method to assess variables obtained at base

182 mor levels of EGFR with tumor stage, and the Kaplan-Meier method to estimate patients' median surviva

183 were seen in most diagnostic groups, but the Kaplan-Meier curves flattened out over time.

184 We estimated risk of CRC over time by the Kaplan-Meier method and compared immigrants to controls

185 pericarditis predicts cancer survival by the Kaplan-Meier method and Cox regression using a matched c

186 ts in the full analysis set predicted by the Kaplan-Meier method to be seizure-free at 6 months was 9

187 Survival at day 28 estimated by the Kaplan-Meier method was lower in patients with thrombocy

188 redicted by the nomogram and observed by the Kaplan-Meier method were similar at 3- and 5-year for pa

189 Survival curves were derived by the Kaplan-Meier method, and Cox regression was performed to

190 Survival was estimated by the Kaplan-Meier method, and the relationship between stage

191 s, and survival curves were estimated by the Kaplan-Meier method.

192 cer-specific survival were calculated by the Kaplan-Meier method.

193 Survival outcomes were estimated by the Kaplan-Meier method.

194 or progression-free survival outcomes by the Kaplan-Meier method.

195 tality rates were calculated by dividing the Kaplan-Meier 5-year mortality by 5.

196 nts (age 67+/-16.2 years; 53.7% female), the Kaplan-Meier estimate for stroke/TIA recurrence within 1

197 ed in 51 patients, with no difference in the Kaplan Meier 5-year recurrence rates (10% vs. 23%; p = 0

198 In the Kaplan-Meier analysis at 24 weeks, the rate of death wit

199 With a median follow-up of 39.7 months, the Kaplan-Meier estimate for 2-year overall survival was 98

200 e extracted from the text of articles or the Kaplan-Meier curves independently by investigators who w

201 s with DCB were also superior to PTA per the Kaplan-Meier estimate for primary patency (89.0% versus

202 roportional survival hazards and plotted the Kaplan-Meier survival curves as well as the net chance o

203 tomy (RP), using descriptive statistics, the Kaplan-Meier method, and multivariable Cox proportional

204 US cancer population using an area under the Kaplan-Meier survival curve approach that combined trial

205 In the current study, we used "The Kaplan-Meier plotter" (KM plotter) database to investiga

206 We used the Kaplan-Meier method to estimate 5-year survival and Cox

207 nfidence intervals were calculated using the Kaplan-Meier estimator stratified by the initial CD4 cel

208 valence of epilepsy was determined using the Kaplan-Meier estimator.

209 by treatment cohort was estimated using the Kaplan-Meier method and analyzed using the log rank test

210 OS was analyzed using the Kaplan-Meier method and compared using the log-rank test

211 sion or recurrence) were evaluated using the Kaplan-Meier method and Cox proportional hazards modelin

212 with overall survival was assessed using the Kaplan-Meier method and the log-rank test.

213 rtality and as long-term mortality using the Kaplan-Meier method and using standardized mortality rat

214 t were evaluated and calculated by using the Kaplan-Meier method and were compared by using the log-r

215 r transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and mod

216 Survival estimates were calculated using the Kaplan-Meier method, and multivariable analysis was cond

217 estimated the distribution of TFS using the Kaplan-Meier method, assessing between-group differences

218 OS was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional haz

219 Survival rates were calculated using the Kaplan-Meier method.

220 reatment failures) was assessed by using the Kaplan-Meier method.

221 val probabilities were computed by using the Kaplan-Meier method.

222 ee survivals (RFS) were calculated using the Kaplan-Meier method.

223 recurrence survival was calculated using the Kaplan-Meier method.

224 Survival analysis was performed using the Kaplan-Meier method.

225 Median survival was calculated by using the Kaplan-Meier method.

226 Overall survival was calculated using the Kaplan-Meier method.

227 verall survival was also estimated using the Kaplan-Meier product-limit method and compared with a lo

228 We did survival analyses with the Kaplan-Meier estimator and evaluated using the log-rank

229 Survival curves were estimated with the Kaplan-Meier method and compared by log-rank test.

230 At 2 years, the Kaplan-Meier event rates were 19.3% in the TAVR group an

231 h time-to-event analysis ascertained through Kaplan-Meier estimates.

232 Unadjusted Kaplan-Meier 3-year patient survival rates were computed

233 We used Kaplan-Meier analyses to compare glucocorticoid treatmen

234 We used Kaplan-Meier analysis to evaluate the number of cases of

235 ears of scheduled endocrine therapy, we used Kaplan-Meier and Cox regression analyses, stratified acc

236 We used Kaplan-Meier curves to compare patient survival between

237 We used Kaplan-Meier methods to analyse the cumulative incidence

238 We used Kaplan-Meier survival analysis to adjust for censorship

239 Using Kaplan-Meier survival curves with log-rank tests, health

240 ed-coil domains 1 (TMCO1) risk alleles using Kaplan-Meier and Cox proportional hazards analyses.

241 ity and morbidity events were analyzed using Kaplan-Meier curves and Cox proportional hazards regress

242 Graft survival was analyzed using Kaplan-Meier survival curves and Cox regression analysis

243 rs and long-term outcomes was assessed using Kaplan-Meier analyses and a Cox proportional-hazards reg

244 erculosis-related deaths were assessed using Kaplan-Meier estimates and Cox models.

245 s of long-term mortality were assessed using Kaplan-Meier survival analyses and Cox proportional haza

246 Median survival was assessed by using Kaplan-Meier and log-rank methods.

247 Overall survival was estimated by using Kaplan-Meier survival and univariate Cox proportional ha

248 ree from adverse events was calculated using Kaplan-Meier curves and Cox proportional hazard ratios w

249 noma-related mortality were calculated using Kaplan-Meier estimates, and Cox proportional hazards reg

250 The risk of relapse was calculated using Kaplan-Meier methods, and predictors were determined usi

251 Overall survival (OS) was compared using Kaplan-Meier analysis with log-rank tests and multivaria

252 Overall survival was compared using Kaplan-Meier analysis with log-rank tests, multivariable

253 respect to HNSCC staging were compared using Kaplan-Meier analysis, Cox proportional hazards regressi

254 Survival analysis was conducted using Kaplan-Meier curves, and Cox regression was used to iden

255 OC microarray gene expression datasets using Kaplan-Meier and multivariate Cox regression analyses an

256 Survival was described using Kaplan-Meier curves.

257 Recurrence-free survival was described using Kaplan-Meier product limit methods.

258 Patient survival was determined using Kaplan-Meier analysis and predictors of mortality were i

259 lative lifetime prevalence of epilepsy using Kaplan-Meier approached 90%.

260 us immunosuppressant use was estimated using Kaplan-Meier analysis.

261 nts and other endpoints were estimated using Kaplan-Meier and logistic regression analyses.

262 Outcomes were estimated using Kaplan-Meier for overall survival (OS) and cumulative in

263 he overall survival rate was estimated using Kaplan-Meier method.

264 fidence intervals (CIs) were estimated using Kaplan-Meier methods at 3, 12, and 36 months after treat

265 d disease-free survival were estimated using Kaplan-Meier methods in 130 eyes.

266 ion-free survival rates were estimated using Kaplan-Meier survival curves.

267 djuvant therapy regimen, was evaluated using Kaplan-Meier and Cox proportional hazards analysis.

268 oma skin cancers), which was evaluated using Kaplan-Meier survival analysis and proportional hazards

269 come was survival, which was evaluated using Kaplan-Meyer curves and adjusted Cox proportional hazard

270 Disease-free survival was examined using Kaplan-Meier curves and Cox proportional hazards regress

271 and overall survival (OS) was examined using Kaplan-Meier log-rank survival analysis and multivariate

272 nd outcome of pneumococcal meningitis, using Kaplan-Meier survival curves, bacteriological and histol

273 The conventional approach of using Kaplan-Meier method to calculate the cumulative risk of

274 ated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysi

275 ll survival time and cancer recurrence using Kaplan-Meier curves.

276 between patients with and without RVAD using Kaplan-Meier method and Cox proportional hazards modelin

277 tality were analyzed by NYHA IV status using Kaplan-Meier analysis and Cox proportional hazard models

278 ed the effect of selection for tracing using Kaplan-Meier estimates of reengagement among all patient

279 The model was internally validated using Kaplan-Meier comparison of observed vs predicted mortali

280 rvival was evaluated for up to 9 weeks using Kaplan-Meier survival analysis.

281 Furthermore, the results obtained via Kaplan-Meier analysis demonstrated the potential of radi

282 The primary endpoint was Kaplan-Meier survival to transplant.

283 With Kaplan-Meier analysis, the risk of death increased signi

284 Survival was analyzed with Kaplan-Meier curves.

285 e to regression of seeds were estimated with Kaplan-Meier estimates.

286 ere complete success rates at 24 months with Kaplan-Meier analysis and incidence of adverse events.

287 by stratified univariate log-rank test with Kaplan-Meier curves and by multivariate Cox proportional

288 icular cascade stage at a specific time with Kaplan-Meier survival analysis.

289 patients in the radiofrequency group (1-year Kaplan-Meier event rate estimates, 10.2% and 12.8%, resp

290 d in 143 in the radiofrequency group (1-year Kaplan-Meier event rate estimates, 34.6% and 35.9%, resp

291 The 10-year Kaplan-Meier estimates for RFS in arm A were 90.9% and 6

292 mponent of the dual-design study, the 5-year Kaplan-Meier estimates of the incidence of arrhythmic ev

293 rsonalized cytogenetic profiles, with 5-year Kaplan-Meier estimates ranging from 4% with chromosomes

294 ate ICD therapy, and were reported as 5-year Kaplan-Meier rate estimates.

295 The primary analysis was the 5-year Kaplan-Meier survival rate for each criterion.

296 The 5-year Kaplan-Meier survival rates were 57%, 51%, and 30% for c

297 In patients with DM, E/S reduced the 7-year Kaplan-Meier primary end point event rate by 5.5% absolu

298 Three-year Kaplan-Meier success for GFCS vs JOAG was 75.3% vs 53.3%

299 Two-year Kaplan-Meier estimates of ocular survival and disease-fr

300 d increase in conversion risk after 6 years (Kaplan-Meier).